UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $57.90 and traded as high as $64.18. UCB shares last traded at $64.07, with a volume of 71,706 shares trading hands.
UCB Stock Up 1.2 %
The company’s 50 day moving average price is $57.90 and its two-hundred day moving average price is $47.06.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- How to Invest in Insurance Companies: A Guide
- United Airlines Soars on Earnings Beat
- How to Calculate Inflation Rate
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What to Know About Investing in Penny Stocks
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
